Aardvark Therapeutics, Inc. (NASDAQ:AARD) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Aardvark Therapeutics, Inc. (NASDAQ:AARD) have received an average rating of “Moderate Buy” from the thirteen ratings firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, seven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $25.0909.

AARD has been the subject of several analyst reports. Cantor Fitzgerald restated an “overweight” rating on shares of Aardvark Therapeutics in a report on Friday, November 14th. William Blair started coverage on Aardvark Therapeutics in a report on Friday, December 12th. They set an “outperform” rating on the stock. HC Wainwright reissued a “neutral” rating on shares of Aardvark Therapeutics in a research report on Monday, March 2nd. Royal Bank Of Canada downgraded Aardvark Therapeutics from an “outperform” rating to a “sector perform” rating and decreased their price target for the company from $18.00 to $6.00 in a research note on Monday, March 2nd. Finally, Raymond James Financial reaffirmed a “strong-buy” rating and set a $47.00 price target on shares of Aardvark Therapeutics in a research report on Monday, January 12th.

Aardvark Therapeutics Trading Down 3.2%

Shares of AARD stock opened at $5.09 on Friday. The firm’s fifty day moving average price is $11.93 and its two-hundred day moving average price is $11.84. Aardvark Therapeutics has a 1 year low of $4.74 and a 1 year high of $17.94. The firm has a market capitalization of $110.81 million and a P/E ratio of -2.40.

Hedge Funds Weigh In On Aardvark Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AARD. Goldman Sachs Group Inc. bought a new stake in Aardvark Therapeutics during the first quarter worth $153,000. Geode Capital Management LLC lifted its stake in Aardvark Therapeutics by 129.7% in the second quarter. Geode Capital Management LLC now owns 136,927 shares of the company’s stock valued at $1,851,000 after acquiring an additional 77,327 shares during the last quarter. New York State Common Retirement Fund bought a new position in shares of Aardvark Therapeutics in the 2nd quarter valued at about $99,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new position in shares of Aardvark Therapeutics in the 2nd quarter valued at about $42,000. Finally, Bank of America Corp DE increased its stake in shares of Aardvark Therapeutics by 72.9% during the 2nd quarter. Bank of America Corp DE now owns 7,989 shares of the company’s stock worth $108,000 after purchasing an additional 3,369 shares during the last quarter.

About Aardvark Therapeutics

Aardvark Therapeutics, Inc is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the discovery and development of small-molecule modulators of the retinoic acid receptor–related orphan receptor gamma (RORγ). RORγ plays a central role in T-helper 17 (Th17) cell differentiation and inflammatory processes. By targeting this transcription factor, Aardvark aims to address a range of autoimmune and immune-mediated diseases.

The company’s lead programs consist of selective RORγ inverse agonists designed to suppress pathogenic Th17-driven responses in conditions such as psoriasis, inflammatory bowel disease and other chronic inflammatory disorders.